OncoMed Pharmaceuticals (NASDAQ: OMED) and Albany Molecular Research (NASDAQ:AMRI) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.
Insider & Institutional Ownership
51.7% of OncoMed Pharmaceuticals shares are held by institutional investors. Comparatively, 72.1% of Albany Molecular Research shares are held by institutional investors. 32.8% of OncoMed Pharmaceuticals shares are held by company insiders. Comparatively, 14.5% of Albany Molecular Research shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
OncoMed Pharmaceuticals has a beta of 2.71, indicating that its stock price is 171% more volatile than the S&P 500. Comparatively, Albany Molecular Research has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
This is a summary of recent recommendations for OncoMed Pharmaceuticals and Albany Molecular Research, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Albany Molecular Research||0||4||0||0||2.00|
OncoMed Pharmaceuticals currently has a consensus price target of $6.00, suggesting a potential upside of 33.04%. Albany Molecular Research has a consensus price target of $18.00, suggesting a potential downside of 17.20%. Given OncoMed Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe OncoMed Pharmaceuticals is more favorable than Albany Molecular Research.
Earnings and Valuation
This table compares OncoMed Pharmaceuticals and Albany Molecular Research’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|OncoMed Pharmaceuticals||$25.15 million||6.79||-$103.10 million||($1.89)||-2.39|
|Albany Molecular Research||N/A||N/A||N/A||($1.43)||-15.20|
Albany Molecular Research has higher revenue, but lower earnings than OncoMed Pharmaceuticals. Albany Molecular Research is trading at a lower price-to-earnings ratio than OncoMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares OncoMed Pharmaceuticals and Albany Molecular Research’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Albany Molecular Research||-5.93%||-13.39%||-3.42%|
OncoMed Pharmaceuticals beats Albany Molecular Research on 7 of the 11 factors compared between the two stocks.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
About Albany Molecular Research
Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
What are top analysts saying about OncoMed Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OncoMed Pharmaceuticals Inc. and related companies.